AXTI Ramps InP Capacity Amid AI Optics Demand but Permits Remain Key

What happened

AXT is accelerating its indium phosphide substrate capacity expansion through 2028, driven by AI optical demand and a backlog exceeding $100M. The company has secured Tier-1 customer adoption, but all manufacturing remains in China, subject to export-permit approvals. In Q1 2026, revenue reached $26.9M with gross margin of 29.6%, yet North America revenue was only $0.2M due to permit constraints. Management continues to state it cannot predict permit timing for U.S. shipments, keeping the core risk intact. The capacity build adds potential upside if permits clear, but without a quantified permit cadence, the investment thesis remains a wait-and-see proposition.

Implication

While the capacity expansion signals long-term demand confidence, the stock's high valuation (P/E -207x) and negative free cash flow (-$10.3M) leave no room for error. The key catalyst remains a measurable increase in U.S.-bound permit approvals, which would enable direct participation in the AI optics market. Without that, the multi-year growth story is contingent on Europe/Japan demand sustaining the backlog conversion. Investors should monitor quarterly reporting for the 'already permitted' revenue floor and any change in management's permit language. The 6-12 month re-assessment window is appropriate; the bull case of $95 requires permit breakthroughs, while the bear case of $40 is plausible if permits remain lumpy.

Thesis delta

The news does not alter the fundamental thesis; it merely extends the capacity expansion timeline to 2028. The binding constraint remains non-forecastable China export-permit timing for U.S. shipments. Until filings provide a quantified permit cadence or North America revenue materially inflects, the wait rating and $45 attractive entry point remain appropriate.